Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte (INCY) has announced the granting of restricted stock unit awards (RSUs) to 16 new employees, totaling 13,351 shares of company common stock. The grants were made under the company's 2024 Inducement Stock Incentive Plan, with both grant date and vesting commencement date set for March 3, 2025.
The awards were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments of 25% each, contingent upon continued employment with the company.
Incyte (INCY) ha annunciato l'assegnazione di premi in azioni riservate (RSU) a 16 nuovi dipendenti, per un totale di 13.351 azioni ordinarie della società. I premi sono stati concessi nell'ambito del 2024 Inducement Stock Incentive Plan dell'azienda, con la data di concessione e la data di inizio della maturazione fissate per il 3 marzo 2025.
I premi sono stati approvati dal comitato per le retribuzioni del consiglio di amministrazione di Incyte come incentivo per i nuovi dipendenti che si uniscono all'azienda, in conformità con la Regola di quotazione Nasdaq 5635(c)(4). Le RSU matureranno in quattro rate annuali uguali del 25% ciascuna, a condizione che il dipendente continui a lavorare per l'azienda.
Incyte (INCY) ha anunciado la concesión de premios de unidades de acciones restringidas (RSUs) a 16 nuevos empleados, totalizando 13,351 acciones ordinarias de la empresa. Las concesiones se realizaron bajo el 2024 Inducement Stock Incentive Plan de la compañía, con la fecha de concesión y la fecha de inicio de la adquisición establecidas para el 3 de marzo de 2025.
Los premios fueron aprobados por el comité de compensación de la junta directiva de Incyte como un incentivo para los nuevos empleados que se unen a la empresa, de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4). Las RSUs se adquirirán en cuatro cuotas anuales iguales del 25% cada una, condicionadas a la continuidad del empleo con la empresa.
Incyte (INCY)는 16명의 신규 직원에게 총 13,351주의 회사 보통주를 포함한 제한된 주식 단위(RSU) 수여를 발표했습니다. 이 수여는 2024 Inducement Stock Incentive Plan에 따라 이루어졌으며, 수여일과 베스팅 시작일은 2025년 3월 3일로 설정되었습니다.
이 상은 신규 직원이 회사에 합류하는 것을 유도하기 위해 Incyte 이사회 보상 위원회에서 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어졌습니다. RSU는 회사에 계속 재직하는 조건으로 25%씩 네 번의 동등한 연간 할부로 베스팅됩니다.
Incyte (INCY) a annoncé l'octroi d'unités d'actions restreintes (RSU) à 16 nouveaux employés, totalisant 13 351 actions ordinaires de la société. Les octrois ont été effectués dans le cadre du 2024 Inducement Stock Incentive Plan de l'entreprise, avec la date d'octroi et la date de début de l'acquisition fixées au 3 mars 2025.
Les récompenses ont été approuvées par le comité de rémunération du conseil d'administration d'Incyte comme une incitation pour les nouveaux employés rejoignant l'entreprise, conformément à la règle de cotation Nasdaq 5635(c)(4). Les RSU seront acquises en quatre versements annuels égaux de 25 % chacun, sous réserve de la continuité de l'emploi au sein de l'entreprise.
Incyte (INCY) hat die Vergabe von Restricted Stock Units (RSUs) an 16 neue Mitarbeiter angekündigt, die insgesamt 13.351 Aktien des Unternehmens umfassen. Die Vergaben erfolgten im Rahmen des 2024 Inducement Stock Incentive Plan des Unternehmens, wobei sowohl das Vergabedatum als auch das Datum des Beginns der Vesting auf den 3. März 2025 festgelegt wurden.
Die Auszeichnungen wurden vom Vergütungsausschuss des Vorstands von Incyte genehmigt, um neue Mitarbeiter zu motivieren, die dem Unternehmen beitreten, und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die RSUs werden in vier gleichen jährlichen Raten von jeweils 25 % fällig, vorausgesetzt, der Mitarbeiter bleibt weiterhin im Unternehmen beschäftigt.
- Employee retention strategy through equity compensation
- Successful talent acquisition with 16 new hires
- Potential dilution of existing shareholders from 13,351 new shares
Each RSU vests as to
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250307751118/en/
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte
FAQ
How many shares of RSUs did Incyte (INCY) grant to new employees in March 2025?
What is the vesting schedule for Incyte's (INCY) March 2025 RSU grants?
Under which plan were Incyte's (INCY) March 2025 RSU grants made?
What Nasdaq rule governs Incyte's (INCY) March 2025 inducement grants?
